INmune Bio extends shareholder rights plan to Dec 2025 and grants stock options to executives and directors

Inmune Bio, Inc.

Rights Agreement amended to extend expiration to December 30, 2025.
Non-employee directors each granted options for 32,500 shares at $5.05, vesting Dec 5, 2026.
CEO Raymond Tesi granted options for 226,000 shares at $5.05, vesting Dec 5, 2026.
CFO David Moss granted 223,000 options; CSO Mark Lowdell 140,000 options, same terms.
All grants expire December 4, 2034 and were made under the 2021 Stock Incentive Plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.